Henrietta Lacks’s family sues another pharmaceutical company
By Clarence Williams,
The Washington Post
| 08. 10. 2023
The heirs of Henrietta Lacks, the Black woman who died in the 1950s and whose cells have been reproduced for decades in scientific research, filed suit Thursday in Baltimore federal court alleging that a pharmaceutical company profited from using cells without the consent of Lacks or her family.
The action comes almost two weeks after Lacks’s descendants settled litigation with another biotech company that had allegedly profited from the cells despite knowing that they were extracted without her consent. Terms of the litigation were not released.
Thursday’s suit asks a court to force Ultragenyx, a California-based company that focuses on the development and commercialization of products for rare and genetic diseases, to stop the use of Lacks’s cell line without the permission of her family; to create a “trust” for the cells in possession; to reveal the profits earned from use of the cells; and to provide financial relief.
Lacks was a Baltimore mother of five when she was diagnosed with cervical cancer in 1951 at age 31. A Johns Hopkins Hospital doctor took a sample from her tumor without...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024